These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34567261)

  • 1. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
    de Jesus VHF; Riechelmann RP
    Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
    Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
    Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.
    Galvano A; Castiglia M; Rizzo S; Silvestris N; Brunetti O; Vaccaro G; Gristina V; Barraco N; Bono M; Guercio G; Graceffa G; Fulfaro F; Gori S; Bazan V; Russo A
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
    Parmar A; Chaves-Porras J; Saluja R; Perry K; Rahmadian AP; Santos SD; Ko YJ; Berry S; Doherty M; Chan KKW
    Crit Rev Oncol Hematol; 2020 Jan; 145():102817. PubMed ID: 31955005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.
    Di Costanzo F; Di Costanzo F; Antonuzzo L; Mazza E; Giommoni E
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of adjuvant gemcitabine
    Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
    Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
    Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
    Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
    Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
    BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
    Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
    J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
    Li H; Guo Y; Sun X; Lu Y; Chang S; Wang X; Gao S; Gao C; Zhao T
    Front Oncol; 2023; 13():1276037. PubMed ID: 37909023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis.
    de Jesus VHF; Riechelmann RP
    Ecancermedicalscience; 2021; 15():1305. PubMed ID: 34824628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel
    Demaziere A; Mourgues C; Lambert C; Trevis S; Bertucat H; Grange I; Pezet D; Sautou V; Jary M; Gagnière J
    Ther Adv Med Oncol; 2024; 16():17588359241259635. PubMed ID: 38882442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
    de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
    Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRINOX
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
    World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and resource utilization of
    Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
    Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.